EPS for BioCryst Pharmaceuticals, Inc. (BCRX) Expected At $-0.20

October 13, 2018 - By Richard Conner

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) LogoInvestors sentiment increased to 0.97 in 2018 Q2. Its up 0.01, from 0.96 in 2018Q1. It increased, as 8 investors sold BioCryst Pharmaceuticals, Inc. shares while 30 reduced holdings. 17 funds opened positions while 20 raised stakes. 85.05 million shares or 0.98% less from 85.89 million shares in 2018Q1 were reported.
Amalgamated Bank holds 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 14,835 shares. Group One Trading Limited Partnership invested 0% in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Parametric Port Assocs Ltd Liability Co stated it has 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Alliancebernstein Lp has 0% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 116,320 shares. Fmr Ltd Limited Liability Company reported 4.42 million shares or 0% of all its holdings. Spark Invest Management Ltd Company owns 0.02% invested in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for 60,200 shares. Teacher Retirement Of Texas reported 14,060 shares. Millennium Mgmt Limited Liability reported 1.70 million shares. Voya Mngmt Limited Liability Company reported 42,157 shares or 0% of all its holdings. Huntington National Bank has invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Citigroup invested 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Paloma Prtn Mngmt Company invested in 30,300 shares or 0% of the stock. Credit Suisse Ag invested in 0% or 62,417 shares. Deutsche National Bank Ag, Germany-based fund reported 568,146 shares. Principal Financial stated it has 0% of its portfolio in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Since June 1, 2018, it had 0 insider purchases, and 1 sale for $265,306 activity.

Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report $-0.20 EPS on November, 6.They anticipate $0.02 EPS change or 11.11 % from last quarter’s $-0.18 EPS. After having $-0.19 EPS previously, BioCryst Pharmaceuticals, Inc.’s analysts see 5.26 % EPS growth. The stock increased 5.73% or $0.38 during the last trading session, reaching $7.01. About 439,729 shares traded. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has risen 34.80% since October 13, 2017 and is uptrending. It has outperformed by 19.18% the S&P500.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Coverage

Among 2 analysts covering BioCryst (NASDAQ:BCRX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. BioCryst had 2 analyst reports since May 9, 2018 according to SRatingsIntel. As per Wednesday, May 9, the company rating was maintained by H.C. Wainwright.

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company has market cap of $768.25 million. The firm markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU. It currently has negative earnings. It also has various ongoing development programs, including BCX7353 and second generation oral inhibitors of plasma kallikrein for hereditary angioedema; and galidesivir, a broad spectrum viral RNA polymerase inhibitor that is indicated to treat filoviruses, as well as forodesine, an oral purine nucleoside phosphorylase inhibitor for use in oncology.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>